Inclisiran in Chronic Kidney Disease Patients: A Real-World Experience

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Cardiovascular disease is a major concern for chronic kidney disease (CKD) patients.
• Hypercholesterolemia, particularly high LDL cholesterol, is a significant cardiovascular risk factor in CKD.
• Statins, a first-line therapy, are often poorly tolerated by CKD patients due to side effects like rhabdomyolysis.

Purpose of the Study:

• To evaluate the efficacy and safety of Inclisiran as an alternative hypercholesterolemia treatment in CKD patients.
• To assess Inclisiran's impact on LDL cholesterol and estimated glomerular filtration rate (eGFR) in this population.

Main Methods:

• An observational study included 32 CKD patients (mean age 60.2 years) with hypercholesterolemia and coronary artery disease.
• Patients received Inclisiran 284 mg at baseline, 3 months, and 6 months.
• Mean baseline eGFR was 36.93 ml/min/m2; 4 patients had type 2 diabetes.

Main Results:

• Inclisiran treatment resulted in nearly a 50% reduction in total and LDL cholesterol after 12 months.
• No significant changes were observed in eGFR values during the study period.
• One patient experienced a myocardial infarction; no drug-related side effects were reported.

Conclusions:

• Inclisiran presents a viable therapeutic option for hypercholesterolemia in statin-intolerant CKD patients.
• The treatment effectively achieves guideline-recommended LDL cholesterol targets.
• Inclisiran demonstrates a favorable safety profile in this patient cohort.